Overview

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
Phase:
Phase 3
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Buprenorphine